The enhanced glutamatergic drive is the result of glutamate (Glu) being assiduously released from gliomas via system Xc transporter (SXC) encoded by the SLC7A11 gene that is upregulated in about 54% of glioma patients4. Here, SLC7A11 is linked to central nervous system cancer.